Healthcare Sector Averages 51/100 Score, 31.2x P/E, -17.6% ROE

Healthcare sector averages mediocre scores (51/100 composite) with high P/E 31.2 and negative ROE -17.6%, yet top stocks like NUTX (P/E 2.38, ROE 78.92%) and SIGA (P/E 7.13, ROE 43.61%) show strong value and quality.

The healthcare sector's average scores of 51-52/100 and P/E of 31.2 appear reasonably valued, but the stark -17.6% ROE signals widespread profitability challenges amid policy uncertainty and headwinds. This valuation discount contrasts with strong tailwinds like aging demographics, AI innovation, and expected 2025 M&A rebound, potentially drawing value investors to quality opportunities in subsectors like biopharma and medtech.

• Avg P/E of 31.2 exceeds S&P 500 historical norm of ~20-25, signaling premium valuations amid projected 7% healthcare EBITDA CAGR to 2028 versus broader market growth, though standouts like NUTX (P/E 2.38) and SIGA (P/E 7.13) trade at deep discounts.

• Avg ROE of -17.6% sharply trails S&P 500 benchmark of 15%, highlighting sector profitability challenges from post-pandemic pressures, contrasted by high performers like HALO (179.14%) and NUTX (78.92%) demonstrating recovery potential.

• Avg Valuation Score 52/100 indicates fair but unremarkable pricing versus market norms, with 7 of top 10 stocks (e.g., GSK 71/100, INCY 70/100) scoring above sector average, amid healthcare stocks' 2025 underperformance to broader indices.

• Avg Quality Score 52/100 matches valuation peer, lagging implied S&P 500 quality benchmarks, yet top stocks like SIGA (inferred high via 43.61% ROE) and CPRX show superior fundamentals amid 8% HST revenue pool CAGR.

• 1084 stocks tracked spans diverse market caps from $468M (SIGA) to $93.7B (GSK), with median ~$2-10B implying mid-cap dominance versus large-cap S&P 500 weightings, supporting M&A surge projections for 2025.

• Top decile P/B averages ~5.8x (e.g., HALO 25.2x outlier) well above historical healthcare norms of 3-4x, reflecting growth premiums in HST segments growing at 9% CAGR, despite sector ROE weakness.

• Composite Score 51/100 trails market benchmarks, with value outliers like NUTX (73/100 Valuation, 78.92% ROE) offering educational contrasts to sector drags amid 2025 policy overhang easing.

Valuation Opportunity

Healthcare sector averages a 52/100 valuation score, with P/E at 31.2 amid relative lows vs. S&P 500. Top stocks like NUTX (73/100, P/E 2.38) and INCY (70/100, P/E 15.28) trade below peers, signaling potential entry points. Recent underperformance prices in policy

Risks

like IRA negotiations, creating selective value.

Quality Leaders

Sector ROE averages -17.6%, but standouts like HALO (179.14%) and NUTX (78.92%) show strong returns. SIGA (43.61%, P/E 7.13) and CRMD (38.35%) also excel on

quality metrics. Insight: These firms demonstrate resilience amid patent cliffs and regulation.

Sector Headwinds

Healthcare lagged S&P 500 with Q2 2025's worst relative return, driven by policy uncertainty, tariffs, and patent losses. Avg composite score 51/100 reflects margin pressures from labor and payer shifts. Selective recovery possible as fears peak.

Emerging

Catalysts

Innovation in obesity drugs, AI efficiencies, and M&A activity offer tailwinds, alongside aging demographics. MedTech subsector outperforms, potentially boosting hospitals. Private markets stabilize despite lower fundraising.

Healthcare sector offers value amid low average valuations (P/E 31.2) and standout stocks like NUTX, INCY, and SIGA with superior scores and ROE. Policy overhangs are easing, boosting biotech/pharma recovery and M&A potential into 2026. Watch earnings stabilization, regulatory shifts, and M&A for upside catalysts.